Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

(2013) Dagmar Kubitza et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Apixaban: an Oral Direct Factor-Xa Inhibitor

(2012) David Jiménez et al.   ADVANCES IN THERAPY

Clinical Challenges in a Patient With Dabigatran-Induced Fatal Hemorrhage

(2012) Ennie L. Cano et al.   American Journal Geriatric Pharmacotherapy

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors

(2012) Scott Kaatz et al.   AMERICAN JOURNAL OF HEMATOLOGY

Dabigatran-Induced Gastrointestinal Bleeding in an Elderly Patient with Moderate Renal Impairment

(2012) Maura K Wychowski et al.   ANNALS OF PHARMACOTHERAPY

Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis

(2012) Victoria L Baczek et al.   BMC Family Practice

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran Etexilate

(2011) Graeme J. Hankey et al.   CIRCULATION

Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate

(2011) Elise S. Eerenberg et al.   CIRCULATION

Preventing Venous Thromboembolism Following Orthopedic Surgery in the United States

(2011) Steven B. Deitelzweig et al.   CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

Laboratory assessment of new anticoagulants

(2011) Meyer M. Samama et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Edoxaban

(2011) A. John Camm et al.   DRUGS

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor

(2011) Kan He et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Renal Profiles of Anticoagulants

(2011) Sebastian Harder   JOURNAL OF CLINICAL PHARMACOLOGY

In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban

(2011) M. J. Gnoth et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The Coagulopathy of Chronic Liver Disease

(2011) Armando Tripodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

(2011) Ola Dahl et al.   THROMBOSIS AND HAEMOSTASIS

Warfarin therapy in patients with venous thromboembolism: Patterns of use and predictors of clinical outcomes

(2010) Steven B. Deitelzweig et al.   ADVANCES IN THERAPY

Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism

(2010) Bengt I. Eriksson et al.   Annual Review of Medicine

Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin

(2010) Wolfgang G. Eisert et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Rivaroxaban: A New Oral Factor Xa Inhibitor

(2010) Elisabeth Perzborn et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

(2010) Dagmar Kubitza et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

(2010) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

Tissue Distribution and Elimination of [14C]Apixaban in Rats

(2010) L. Wang et al.   DRUG METABOLISM AND DISPOSITION

Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement

(2010) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development

(2010) Mike Ufer   THROMBOSIS AND HAEMOSTASIS

Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty

(2010) Michael Rud Lassen et al.   THROMBOSIS AND HAEMOSTASIS

Haemostasis and thrombosis in liver disease

(2009) Lara N. Roberts et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects

(2009) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans

(2009) C. Weinz et al.   DRUG METABOLISM AND DISPOSITION

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement

(2009) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Antithrombotic Drugs

(2008) Jeffrey I. Weitz et al.   CHEST

Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development

(2008) Bengt I Eriksson et al.   CLINICAL PHARMACOKINETICS

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

(2008) N. Raghavan et al.   DRUG METABOLISM AND DISPOSITION

Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment

(2008) Joachim Stangier et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Apixaban, an oral, direct and highly selective factor Xa inhibitor:in vitro, antithrombotic and antihemostatic studies

(2008) P. C. WONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Relevance of clotting tests in liver disease

(2008) J Thachil   POSTGRADUATE MEDICAL JOURNAL